Israeli drugmaker Teva has appointed former Sandoz and Biogen executive Richard Francis to succeed current CEO Kare Schultz, who is scheduled to retire at the end of this year.
The North Ireland Protocol has been a source of tension between the UK and EU since it came into force at the start of 2021 – and, according to one pharma company, the end of the so-called
The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug i
Any lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor tanezumab looks to have been dashed after the EMA's human medicines committe
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.